Current Appointments & Affiliations
Associate Professor of Medicine
·
2023 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2018 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
A Phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancer.
Journal Article Cancer · November 2025 BackgroundTreatment options for patients with advanced non-small cell lung cancer (NSCLC) with disease progression following immune checkpoint inhibitor (ICI) and platinum-based chemotherapy are limited. GT103 is a fully human immunoglobulin G3 mo ... Full text CiteUpdated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report.
Journal Article J Thorac Oncol · October 2025 INTRODUCTION: The PHAROS primary analysis revealed robust antitumor activity and acceptable safety with encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC). We report results after 18 months of additional follow-up. ME ... Full text Link to item CitePoziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity.
Journal Article Nat Commun · September 24, 2025 EGFRex20 insertions (EGFRex20ins) can be classified as near- and far-loop based on the insertion location, however, the impact of location on responses to various EGFR tyrosine kinase inhibitors (TKIs) is poorly understood. In vitro studies show that afati ... Full text Link to item CiteRecent Grants
A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of CRB-601, a Monoclonal Antibody against Integrin ?v?8, in Patients with Advanced Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by Corbus Pharmaceuticals, Inc. · 2025 - 2030A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with Small Cell Lung Cancer (SCLC)(DeLLphi-309)
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2025 - 2030SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 express
Clinical TrialPrincipal Investigator · Awarded by Lilly USA, LLC · 2025 - 2030View All Grants
Education, Training & Certifications
Indiana University, School of Medicine ·
2008
M.D.